On the evening of September 2, Tengsheng bo pharmaceutical current personnel "earthquake" involved the resignation of the company's executive directors, the appointment of executive directors, changes in the composition of the strategic committee and the appointment of China R&D supervisors and general managers in Greater China
.
According to the announcement, Luo Yongqing has resigned as executive director, president and general manager of Tengsheng Bo Pharmaceutical in Greater China and as CEO (chief executive officer) of Tengsheng Huachuang, a subsidiary of Tengsheng Bo Pharmaceutical
.
Dr.
Qing Zhu, Senior Vice President and Head of The Biopharmaceutical Division, will serve as Head of R&D in China, effective
October 1, 2022.
Dr.
Ankang Lee, Chief Strategy Officer and Chief Financial Officer, will join the Board as Executive Director on 30 September and take over as CEO of Tengsheng Huachuang
.
Xu Liang, Vice President of Scientific and Medical Affairs, will take over as Senior Vice President and General Manager of Greater China, effective
September 16, 2022.
It is understood that Luo Yongqing's main work this year is to promote the production and supply of ampavivir monoclonal antibody and romizumab preparations
.
This monoclonal antibody was developed by Tengsheng Huachuang, a holding company of Tengsheng Bo Pharmaceutical, and was approved for listing
by the State Food and Drug Administration in early December 2021.
Prior to joining Tengsheng Bo Pharmaceutical, Luo Yongqing worked for multinational pharmaceutical companies such as Merck, Novartis, Roche and Gilead, serving as Global Vice President and General Manager of Gilead China, and in September 2020, Luo Yongqing joined Tengsheng Bo Pharmaceutical as President and General Manager of Greater China, continuing to focus on the field of
public health.
His whereabouts after leaving this time deserve the attention
of the industry.
According to the data, Tengsheng Bo Pharmaceutical has headquarters
in China and the United States.
The company focuses on the development and commercialization
of innovative drugs in the areas of infectious diseases, liver and lung diseases, COVID-19 and HIV.
A pipeline of more than 10 innovative product candidates for infectious diseases and CNS central nervous system diseases has been established, covering preclinical to clinical phase projects
.
Previously, the combination therapy of "amphavir monoclonal antibody" and "romizumab" of Tengsheng Bo Pharmaceuticals has received high attention, and since the drug was approved for listing at the end of last year, the company announced the commercialization of the product in China in July 2022, and the price is expected to be within
10,000 yuan.
However, from the price of the drug in Gansu emergency network on July 11, the price of each of the two monoclonal antibodies is "not higher than the national minimum price of 2417 yuan", the decline is very obvious, and the industry expects that with the listing of more drugs, the market space of the drug will be squeezed
again.
According to financial data, the revenue of Tengsheng Bo Pharmaceutical in 2019, 2020 and 2021 was 20.
339 million yuan, 84.
625 million yuan and 99 million yuan respectively, and the loss (net loss) during the year was 521 million yuan, 1.
283 billion yuan and 4.
191 billion yuan
, respectively.
For the loss, Tengsheng Bo Pharmaceutical once explained in the prospectus that most of the company's operating losses were caused by
research and development expenses and administrative expenses.
In terms of expenditure, Tengsheng Bo Pharmaceutical's R&D expenditure in 2019, 2020 and 2021 was 83.
785 million yuan, 876 million yuan and 495 million yuan respectively, and the input cost increased
sharply before 2021.
It is worth mentioning that Tengsheng Bo Pharmaceutical has gained the enthusiasm of capital at the beginning of its establishment, and in 2018 and 2019, it has successively obtained series A and B rounds of financing, with a total financing of 260 million US dollars, and the investors include Yunfeng Fund, Sequoia Capital, Tonghe Yucheng, Boyu Capital, ARCH Venture Partners and Blue Pool Capital
.
